September 16, 1999
AMERIPATH ACQUIRES TEXAS PATHOLOGY PRACTICE

Riviera Beach, FL, September 16, 1999 -- AmeriPath, Inc. (Nasdaq: PATH), a physician group practice and laboratory management company focused on anatomic pathology services, announced today that it has completed the acquisition of Pathology Associates of Texas, a hospital-based pathology practice located in the Dallas/Fort Worth area. The practice had annualized net revenues of $5.6 million. Terms of the transaction were not disclosed.

Pathology Associates is AmeriPath's eleventh acquisition in the state of Texas and its fifth in the Dallas/Fort Worth area. The practice employs nine physicians, bringing the total of AmeriPath physicians to 273. The practice has established an outstanding reputation with over 25 years of operating history and provides pathology services for two hospitals in the Harris Methodist Health System representing over 500 beds and approximately 300 referring physicians. Pathology Associates also provides anatomic pathology services to three reference laboratories, including Quest Diagnostics, Inc.

"The addition of Pathology Associates of Texas will enhance our position and regional business model in the state of Texas," said James C. New, Chairman and CEO of AmeriPath. "This is of strategic significance to our growth in this market and complements our existing relationship with Quest Diagnostics. We now have 89 physicians in five major cities, making our densification of Texas almost complete."

AmeriPath, Inc. is the nation's leading physician group practice and laboratory management company focused on providing anatomic pathology services to physicians, hospitals, national clinical laboratories, and managed care organizations. The Company presently operates in twelve states and employs 273 pathologists who provide medical services through outpatient pathology laboratories, hospital inpatient laboratories, and outpatient surgery centers.

...................................................................................................................

This release contains certain forward-looking statements regarding AmeriPath, including its operations and prospects. Past performance is not necessarily indicative of future results. In addition, AmeriPath's actual results could differ materially from the results anticipated in these forward-looking statements as a result of uncertainties, including risks relating to demand, pricing, government regulation, payments and reimbursement, changes on reimbursement coding guidelines, dependence upon contracts and pathologists, acquisitions and affiliations, integration of acquired practices, the market for pathology services, competition, and other factors identified in AmeriPath's filings with the Securities and Exchange Commission.